Table 4 Univariate and multivariate analyses of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) in relation to clinical parameters

LipB mRNA RQ

Low vs high tertile

92

1.6

0.7-3.3

0.220

64

2.5

1.1-5.6

0.020

88

2.2

1.1-4.3

0.030

LipB IHC

Continuous

92

1.4

0.6-3.3

0.400

67

0.99

0.3-2.4

0.980

91

1.3

0.6-2.8

0.499

LipB IHC

Categoric

IHC = 2 vs IHC ≤ 1

92

0.8

0.4-1.6

0.604

67

0.81

0.4-1.6

0.552

91

0.9

0.5-1.7

0.892

IHC = 3 vs IHC ≤ 1

1.7

0.7-3.7

0.183

1.15

0.4-2.9

0.764

1.4

0.6-3.1

0.353

Age (years)

>60 vs ≤60

92

2.0

1.1-3.7

0.017

67

1.15

0.6-2.1

0.660

91

1.85

1.1-3.2

0.026

FIGO stage

III-IV vs I-II

92

8.1

2.5-26.2

<0.01

67

6.6

2.5-17.1

<0.01

91

7.8

2.8-21.7

<0.01

Residual tumor (cm)

RT > 0 vs RT = 0

92

3.7

1.8-7.8

<0.01

67

2.4

1.2-4.6

0.010

91

3.4

1.7-6.5

<0.01

Presence of ascites

Yes vs no

92

2.6

1.4-5.1

0.003

67

2.8

1.4-5.4

0.002

91

2.6

1.4-4.7

<0.01

Lymph node involvement

Positive vs negative

73

1.9

0.9-4.0

0.04

58

3.4

1.7-6.7

0.001

73

2.8

1.4-5.2

0.002

Multivariate survival analysis

Variables

OS

DFS

PFS

N

HR

95% CI

p

N

HR

95% CI

p

N

HR

95% CI

p

LipB mRNA RQ

Low vs high tertile

92

1.8

0.9-3.9

0.103

64

3.9

1.7-9.1

0.001

88

2.8

1.4-5.8

0.004

FIGO stage

III-IV vs I-II

92

5.1

1.2-20.5

0.022

67

13.7

4.3-43.2

<0.01

91

5.8

1.7-19.4

0.004

Residual tumor (cm)

RT > 0 vs RT = 0

92

1.1

0.4-2.9

0.799

67

4.9

0.07-0.57

0.003

91

1.02

0.4-2.3

0.964

Presence of ascites

Yes vs no

92

1.6

0.8-3.4

0.180

67

3.3

1.3-8.3

0.009

91

1.8

0.9-3.6

0.095